Sareum Holdings PLC on Monday announced it has received a patent allowance for the development of crystalline forms of SDC-1801 in China.
The Cambridge, England-based pharmaceutical company said it received a notice of allowance from the China National Intellectual Property Administration, in response to a patent application protecting certain crystalline forms of SDC-1801.
SDC-1801 is a dual TYK2/JAK1 kinase inhibitor being developed as a potential new therapeutic for a wide range of autoimmune diseases.
Sareum expects the patent to be granted at the end of 2024, and it is the first patent to protect crystalline forms of SDC-1801 in any territory. Sareum’s applications in the US, Europe and Japan are currently under review.
Chief Scientific Officer John Reader said: ‘We welcome the additional allowance from the Chinese Patent Office, building on the recent approval of patents protecting the molecular structure of SDC-1801 in all major territories. This patent, covering various crystal forms, complements our existing molecular structure patents and extends the lifecycle of our patent estate. Combined with the encouraging data from the Phase 1a trial, this strengthened IP position gives us greater confidence as we look to advance SDC-1801 through clinical development, aiming to address unmet medical needs in various autoimmune diseases.’
Shares in Sareum Holdings were up 8.6% at 28.78 pence each in London on Monday afternoon.
Copyright 2024 Alliance News Ltd. All Rights Reserved.
